Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMNASDAQ:CRONNASDAQ:SLSTSE:TEV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$8.30-18.2%$9.15$0.06▼$14.93$600.01M0.76573,212 shs24,056 shsCRONCronos Group$1.91$1.92$1.60▼$2.54$736.65M1.041.35 million shs1.11 million shsSLSGalena Biopharma$1.57+0.6%$1.56$0.77▼$2.12$155.65M2.251.58 million shs2.54 million shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+14.00%+14.00%+14.00%-15.08%-75.49%CRONCronos Group-1.04%-2.05%-10.75%+3.24%-18.38%SLSGalena Biopharma-3.11%+1.30%-4.29%+28.93%+24.80%TEVTervita0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.8056 of 5 stars3.50.00.00.01.91.70.0CRONCronos Group2.7591 of 5 stars0.05.00.00.03.30.02.5SLSGalena Biopharma0.5476 of 5 stars0.01.00.00.02.81.70.6TEVTervitaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.003,213.25% UpsideCRONCronos Group 0.00N/AN/AN/ASLSGalena Biopharma 0.00N/AN/AN/ATEVTervita 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$170K3,529.45N/AN/A$0.20 per share41.50CRONCronos Group$117.61M6.26$0.00 per share4,104.70$2.90 per share0.66SLSGalena Biopharma$1M156.65N/AN/A$0.13 per share12.08TEVTervitaC$1.36B0.00N/A29.62C$1.58 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACRONCronos Group$41.08M$0.1314.6963.6743.3139.69%-0.07%-0.07%8/6/2025 (Estimated)SLSGalena Biopharma-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)TEVTervitaN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ALatest AIM, CRON, SLS, and TEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSGalena Biopharma-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million3/20/2025Q4 2024SLSGalena Biopharma-$0.1067-$0.08+$0.0267-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ASLSGalena BiopharmaN/AN/AN/AN/AN/ATEVTervitaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CRONCronos GroupN/A27.8026.75SLSGalena BiopharmaN/A4.644.64TEVTervita440.441.000.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CRONCronos Group8.71%SLSGalena Biopharma17.38%TEVTervitaN/AInsider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CRONCronos Group7.30%SLSGalena Biopharma1.40%TEVTervitaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2072.29 million68.74 millionNot OptionableCRONCronos Group450385.68 million357.53 millionOptionableSLSGalena Biopharma1099.78 million98.38 millionNot OptionableTEVTervita36,800115.66 millionN/ANot OptionableAIM, CRON, SLS, and TEV HeadlinesRecent News About These CompaniesTev MonninFebruary 16, 2024 | health.usnews.com'Tu zini, ka tev ir balss'. Dzejniece Inga Gaile par filmu 'Starp revolūcijām'September 2, 2023 | delfi.lv‘Beautiful Mind’ Oscar winner honors his father, Tev Goldsman of Kaua’iAugust 28, 2023 | thegardenisland.comAccelerating Electrons To TeV Levels Using Curved Laser BeamsAugust 7, 2023 | hackaday.comUnderstanding Risk for Venous Thromboembolism (VTE)January 21, 2023 | healthline.comTevva begins mass production of medium-duty electric truckJanuary 13, 2023 | newatlas.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAlphabet Enters a Bull Market: Is It Time to Buy?By Ryan Hasson | June 14, 2025View Alphabet Enters a Bull Market: Is It Time to Buy?Micron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment Target's Big Bet: Is It a Cheap Stock or a Value Trap? By Jeffrey Neal Johnson | May 29, 2025View Target's Big Bet: Is It a Cheap Stock or a Value Trap? Will Warner Bros. Discovery’s Split Produce Double the Upside?By Jeffrey Neal Johnson | June 11, 2025View Will Warner Bros. Discovery’s Split Produce Double the Upside?MongoDB Affirms Outlook and Accelerates Stock Price ReversalBy Thomas Hughes | June 6, 2025View MongoDB Affirms Outlook and Accelerates Stock Price ReversalAIM, CRON, SLS, and TEV Company DescriptionsAIM ImmunoTech NYSE:AIM$8.30 -1.85 (-18.23%) Closing price 03:59 PM EasternExtended Trading$8.90 +0.60 (+7.29%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Cronos Group NASDAQ:CRON$1.91 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.93 +0.02 (+1.05%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Galena Biopharma NASDAQ:SLS$1.57 +0.01 (+0.64%) Closing price 04:00 PM EasternExtended Trading$1.55 -0.02 (-1.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tervita TSE:TEVTervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
